Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
Diseases and Conditions Researched
What is the purpose of this trial?
To investigate whether PF-05212384 in combination with irinotecan is superior to cetuximab in combination with irinotecan in prolonging PFS in patients with KRAS and NRAS wild type mCRC who have progressed following prior treatment with irinotecan, oxaliplatin, and fluoropyrimidine.
Click here for detailed participation information for this trial.
|Sponsor:||Pfizer Inc., U.S. Pharmaceuticals Group|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.